$23 Million

Quotient Limited

Follow-on Offering

Bookrunner, June 2022

Quotient Limited is a commercial-stage diagnostics company committed to reducing healthcare costs and improving patient care through the provision of innovative ways to test within blood grouping and donor disease screening, commonly referred to as transfusion diagnostics. MosaiQ, the Company’s proprietary technology platform, will initially comprise two separate microarrays, one for immunohematology (IH) and one for serological disease screening (SDS). The Company is also developing a third microarray for molecular disease screening.